US OptionsDetailed Quotes
CBUS241220P2500
- 0.05
- 0.000.00%
15min DelayClose Nov 29 13:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume8 Open Interest2.50Strike Price0.00Turnover190.87%IV49.59%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0456Delta0.0432Gamma97.20Leverage Ratio-0.0050Theta-0.0001Rho-4.43Eff Leverage0.0011Vega
Cibus Inc Stock Discussion
Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola
Cibus (NASDAQ: CBUS) has successfully completed gene edits in Canola for its 4th mode of action targeting Sclerotinia (White Mold) resistance trait, with greenhouse results expected in Q1 2025. This achievement follows positive field trial results from their 2nd mode of action, which demonstrated enhanced disease resistance. Sclerotinia is identified as the most signif...
Cibus Confirms its Herbicide Tolerance (HT2) Trait Shows Increased Tolerance to a Novel Herbicide for Weed Control in Canola
Cibus Achieves Positive Initial Field Trial Results for Stacked Gene Edited Herbicide Tolerant Traits in Rice
Cibus (Nasdaq: CBUS) has announced positive initial field trial results for a novel weed management solution in rice using stacked gene edited herbicide tolerant traits. The trials showed that using two herbicides provided excellent weed control. This approach could enable farmers to use a comprehensive weed management system with two different modes of action, p...
$Grove Collaborative (GROV.US)$ 16m float / 74% institutional/ 30% CTB
$Acorda Therapeutics (ACOR.US)$ 1.2m float/ 18% institutional/ 37% CTB
$Verastem (VSTM.US)$ 16m float / 40% institutional/ 18% CTB
$Cibus Inc (CBUS.US)$ 16m float / 12% institutional
$Bone Biologics (BBLG.US)$ 27m float / 17% institutional/ 127% CTB
$Greenlane (GNLN.US)$ 1.5m float/ 17% institutional/ 35% CTB
$VistaGen Therapeutics (VTGN.US)$ 7.2m floa...
No comment yet